{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T19:07:57Z","timestamp":1778267277981,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","content-domain":{"domain":["ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.ejim.2013.11.002","type":"journal-article","created":{"date-parts":[[2013,12,2]],"date-time":"2013-12-02T14:15:19Z","timestamp":1385993719000},"page":"63-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patients"],"prefix":"10.1016","volume":"25","author":[{"given":"Alessandra","family":"Iurlo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ubertis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Artuso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Bucelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Radice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Zappa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Mari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agostino","family":"Cortelezzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2013.11.002_bb0005","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S1470-2045(11)70040-7","article-title":"Polypharmacy in elderly patients with cancer: clinical implications and management","volume":"12","author":"Lees","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejim.2013.11.002_bb0010","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.1111\/j.1532-5415.2009.02513.x","article-title":"Cancer treatment in older adults: implications for psychosocial research","volume":"57","author":"Given","year":"2009","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.ejim.2013.11.002_bb0015","first-page":"49","article-title":"Staging and prognosis in chronic myelogenous leukemia","volume":"25","author":"Sokal","year":"1988","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ejim.2013.11.002_bb0020","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejim.2013.11.002_bb0025","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","article-title":"Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party","volume":"117","author":"Gugliotta","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2013.11.002_bb0030","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/cncr.11629","article-title":"Effect of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia","volume":"98","author":"Cortes","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ejim.2013.11.002_bb0035","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ejim.2013.11.002_bb0040","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2013.11.002_bb0045","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/leu.2008.245","article-title":"Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph\/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany","volume":"23","author":"Rohrbacher","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.ejim.2013.11.002_bb0050","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2013.11.002_bb0055","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/bjc.2012.348","article-title":"Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study","volume":"107","author":"Efficace","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejim.2013.11.002_bb0060","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.critrevonc.2012.01.001","article-title":"Tyrosine kinase inhibitor for elderly chronic myeloid leukemia patients: a systemic review of efficacy and safety data","volume":"84","author":"Breccia","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejim.2013.11.002_bb0065","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic \u00f5comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.ejim.2013.11.002_bb0070","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.ejim.2013.11.002_bb0075","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/geront\/10.1_Part_1.20","article-title":"Progress in development of the index of ADL","volume":"1","author":"Katz","year":"1970","journal-title":"Gerontologist"},{"key":"10.1016\/j.ejim.2013.11.002_bb0080","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people: self-maintaining and instrumental activities of daily living","volume":"9","author":"Lawton","year":"1969","journal-title":"Gerontologist"},{"key":"10.1016\/j.ejim.2013.11.002_bb0085","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1046\/j.1532-5415.2001.49281.x","article-title":"The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community","volume":"49","author":"Saliba","year":"2001","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.ejim.2013.11.002_bb0090","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1532-5415.2009.02137.x","article-title":"A comparison of frailty indexes for the prediction of falls, disability, fractures, and mortality in older men","volume":"57","author":"Ensrud","year":"2009","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.ejim.2013.11.002_bb0095","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/j.1532-5415.2009.02394.x","article-title":"Validation and comparison of two frailty indexes: the MOBILIZE Boston study","volume":"57","author":"Kiely","year":"2009","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.ejim.2013.11.002_bb0100","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56A","author":"Fried","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.ejim.2013.11.002_bb0105","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0899-9007(98)00171-3","article-title":"The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients","volume":"15","author":"Vellas","year":"1999","journal-title":"Nutrition"},{"key":"10.1016\/j.ejim.2013.11.002_bb0110","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0022-3956(82)90033-4","article-title":"Development and validation of a geriatric depression screening scale: a preliminary report","volume":"17","author":"Yesavage","year":"1982","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.ejim.2013.11.002_bb0115","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1373\/49.3.433","article-title":"Comparison of eight computer programs for Receiver-Operatic Characteristic Analysis","volume":"49","author":"Stephan","year":"2003","journal-title":"Clin Chem"},{"key":"10.1016\/j.ejim.2013.11.002_bb0120","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.3324\/haematol.2011.041251","article-title":"Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib","volume":"96","author":"Breccia","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.ejim.2013.11.002_bb0125","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ejim.2013.11.002_bb0130","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2013.11.002_bb0135","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","article-title":"Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2013.11.002_bb0140","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ejim.2013.11.002_bb0145","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2013.11.002_bb0150","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2013.11.002_bb0155","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s40266-013-0088-6","article-title":"Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study","volume":"30","author":"Latagliata","year":"2013","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ejim.2013.11.002_bb0160","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11864-008-0060-6","article-title":"Anticancer drug therapy in the older cancer patient: pharmacology and polypharmacy","volume":"9","author":"Lichtman","year":"2008","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ejim.2013.11.002_bb0165","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2013.11.002_bb0170","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.mayocp.2012.10.020","article-title":"Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug\u2013drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents","volume":"88","author":"Bowlin","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejim.2013.11.002_bb0175","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/hon.2020","article-title":"Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia","volume":"31","author":"Latagliata","year":"2013","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ejim.2013.11.002_bb0180","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.leukres.2011.05.015","article-title":"Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant\/intolerant to imatinib","volume":"35","author":"Latagliata","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.ejim.2013.11.002_bb0185","first-page":"1395","article-title":"Severe adverse events associated with the use of second-line BCR\/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities","volume":"96","author":"Valent","year":"2011","journal-title":"Haematologica"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620513009886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620513009886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T05:28:26Z","timestamp":1597123706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620513009886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0953620513009886"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2013.11.002","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2013.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}